A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q, Qi X, Tang P, Fan L, Chen L, Wang S, Liang Y, Hu Y, Wang M, Ren L, Zhang G, Tan X, Yuan L, Du J, Wu X, Wang M, Che H, Lv P, Chen D, Hu J, Li Q, Zhang Y, Yang K, Zhong Y, Chen C, Zhou Z, Qian L, Zhang J, Ma M, Sun Y, Zhang Y, Jiang J.
Shi Q, et al. Among authors: chen l, chen c, chen d.
MedComm (2020). 2023 Dec 7;4(6):e435. doi: 10.1002/mco2.435. eCollection 2023 Dec.
MedComm (2020). 2023.
PMID: 38077249
Free PMC article.